查詢結果分析
相關文獻
- 干擾素治療對慢性C型肝炎的胰島素阻抗以及第2型糖尿病發生率的影響
- Metformin用於治療慢性C型肝炎
- 評估六味地黃丸對糖尿病病患之療效--多中心之雙盲、安慰劑對照性臨床試驗
- 評估六味地黃丸對糖尿病病患之療效--多中心之雙盲、安慰劑對照性臨床試驗
- 評估六味地黃丸對糖尿病病患之療效--多中心之雙盲、安慰劑對照性臨床試驗
- 第2型糖尿病兒童及青少年的臨床照護
- 糖尿病與肌少症
- 慢性C型肝炎之治療
- Genetic Analysis of the Insulin Receptor Gene in Chinese Patients with Extreme Insulin Resistance
- ACARBOSE使用於口服降糖藥物失效之第2型糖尿病患者--臨床評估
頁籤選單縮合
題名 | 干擾素治療對慢性C型肝炎的胰島素阻抗以及第2型糖尿病發生率的影響=Impact of Interferon Based Therapy in HCV Patients on Insulin Resistance and the Risk of Type 2 Diabetes Mellitus |
---|---|
作者姓名(中文) | 蔡明潔; 吳書儀; 劉松臻; 李淳權; | 書刊名 | 內科學誌 |
卷期 | 28:6 2017.12[民106.12] |
頁次 | 頁344-351 |
分類號 | 418.285 |
關鍵詞 | 慢性C型肝炎; 第2型糖尿病; 胰島素阻抗; 持續病毒學反應; 非持續病毒學反應; Chronic hepatitis C; Type 2 diabetes mellitus; Insulin resistance; Sustained virological response; Non-sustained virological response; |
語文 | 中文(Chinese) |
中文摘要 | 慢性C型肝炎已是全球和台灣重要的健康衛生問題,除了肝硬化以及肝癌,肝外的併發症也是臨床照護的重點,包括:混合型冷球蛋白症,慢性腎臟病,淋巴瘤,扁平苔蘚,修格蘭氏症候群,紫質症,發炎性關節炎,憂鬱症,心臟血管疾病,中風以及第2型糖尿病。慢性C肝病人合併第2型糖尿病會增加慢性C肝病人的疾病嚴重性。干擾素治療對於慢性C肝病人雖然有可能會引起短期內胰島素阻抗,但經過許多研究顯示,追蹤6-24個月後會發現接受干擾素治療達到SVR (sustained virologic response,持續病毒反應)的組別,胰島素阻抗相較治療前會有意義的下降,但NSVR組別(non-sustained virologic response,非持續病毒反應組別)干擾素治療前後胰島素阻抗卻沒有意義的改變。除此之外,干擾素治療前血糖正常的慢性C型肝炎病人,SVR組別長期追蹤2-8年血糖異常或是第2型糖尿病的發生率,相較NSVR組別,會有意義的下降0.37~0.48倍。慢性C型肝炎病人接受干擾素治療達到SVR,似乎可以降低第2型糖尿病的發生機會。 |
英文摘要 | Chronic hepatitis C is a global healthy issue. Beside the liver cirrhosis and hepatocellular carcinoma, chronic hepatitis C may lead to several extra-hepatic manifestations including mixed cryoglobulinemia, chronic kidney disease, end-stage renal disease, lymphoma, lichen planus, Sogren's syndrome, depression and type 2 diabetes mellitus. Chronic hepatitis C with type 2 diabets mellitus would increase the rate of decompensated liver cirrhosis, ascites, spontaneous bacterial peritonitis, renal dysfunction, hepatocellular carcinoma, hepatic encephalopathy, portal hypertension and esophageal varices bleeding. Interferon based therapy is the commonest treatment for hepatitis C among many countries. Although interferon based therapy may induce rapidly insulin resistance by counter- regulatory hormones increasing, patients with sustained virologic respond (SVR) among HCV-infected patients with interferon were noted with lower insulin resistance compared to baseline and the reduction of type 2 diabetes mellitus risk compared to non-sustained virologic responders. HCV-infected patients with interferon based therapy with SVR may reduce the risk of type 2 diabetes mellitus. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。